Flurazepam Hydrochloride
Basic information
- CAS
1172-18-5- Standard SMILES
CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21.Cl.Cl- InChIKey
ZIIJJOPLRSCQNX-UHFFFAOYSA-N- Molecular formula
- C21H23ClFN3O.2ClH
- Average molar mass
- 460.8 g/mol
- Monoisotopic mass
- 459.104724
Overview
Flurazepam Hydrochloride can cause developmental toxicity according to state or federal government labeling requirements.
Names & identifiers
- Preferred name
- Flurazepam Hydrochloride
- IUPAC
- 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one;dihydrochloride
Names & synonyms
Flurazepam hydrochlorideFlurazepam dihydrochloride1172-18-5BenozilLinzacLunipaxSomlanInsumin dihydrochlorideNSC-78559Ro 5-6901Flurazepam hydrochloride civID 480
Show more names
2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1,3-dihydro-, dihydrochloride756RDM536MRo-5-6901DTXSID3025334NSC78559RefChem:56332Hydrochloride, FlurazepamDihydrochloride, Flurazepam
Database identifiers
- CAS
1172-18-5- PubChem CID
- 14434
- DTXSID
DTXSID3025334- ChEMBL
CHEMBL3989724- ChEBI
CHEBI:5129- UNII
- 756RDM536M
- EC Number
- 214-630-0
Properties
Computed structural properties
- Topological polar surface area
- 35.9 Ų
- Hydrogen bond donors
- 2
- Hydrogen bond acceptors
- 4
- Rotatable bonds
- 6
- Heavy atoms
- 29
- Formal charge
- 0
- Complexity
- 540
Experimental & physicochemical properties
Solubilitygreater than or equal to 100 mg/mL at 66 °F (NTP, 1992)
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Melting Point406 to 424 °F (decomposes) (NTP, 1992)
Physical DescriptionFlurazepam dihydrochloride is an odorless off-white to yellow crystalline powder. (NTP, 1992)
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
GHS classification
GHS Classification
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P260, P264, P270, P301+P317, P319, P330, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 42 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Hazard information
Regulatory InformationHazard Traits - Developmental Toxicity
Other Safety InformationIMAP assessments - 2H-1,4-Benzodiazepin-2-one, 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-, dihydrochloride: Environment tier I assessment
DOT LabelPoison
Fire HazardsFlash point data for this chemical are not available. It is probably combustible. (NTP, 1992)
Health Hazards
SYMPTOMS: Symptoms of exposure to this compound may include dizziness, drowsiness, light-headedness, staggering, ataxia, severe sedation, lethargy, headache, disorientation, coma, heartburn, upset stomach, nausea, vomiting, diarrhea, constipation, gastrointestinal pain, nervousness, talkativeness, apprehension, irritability, weakness, palpitations, chest pains, body and joint pains and genitourinary complaints. Other symptoms include hypotension, excitement, skin rash, leukopenia, elevated liver enzymes, and jaundice. It has additive effects with alcohol, barbituates, and other central nervous system depressants.
Reactive GroupAmides and Imides
Air and Water Reactions
Chemistry & industry
Pharmacology
FDA Pharmacological Classification
FLURAZEPAM HYDROCHLORIDE
Benzodiazepines [CS]; Benzodiazepine [EPC]
MeSH Pharmacological Classification
Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.
Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.
Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here.
Suppliers
Loading…
Open inquiries
Loading…
Related reactions
0 records
No reaction records under the current filter.
Compound notes
Loading…